Literature DB >> 15340352

Phenotype of schizophrenia: a review and formulation.

C A Tamminga1, H H Holcomb.   

Abstract

The discovery of the pathophysiology(ies) for schizophrenia is necessary to direct rational treatment directions for this brain disorder. Firm knowledge about this illness is limited to areas of phenomenology, clinical electrophysiology, and genetic risk; some aspects of dopamine pharmacology, cognitive symptoms, and risk genes are known. Basic questions remain about diagnostic heterogeneity, tissue neurochemistry, and in vivo brain function. It is an illness ripe for molecular characterization using a rational approach with a confirmatory strategy; drug discovery based on knowledge is the only way to advance fully effective treatments. This paper reviews the status of general knowledge in this area and proposes an approach to discovery, including identifying brain regions of dysfunction and subsequent localized, hypothesis-driven molecular screening.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15340352     DOI: 10.1038/sj.mp.4001563

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  74 in total

1.  Altered integrity of the right arcuate fasciculus as a trait marker of schizophrenia: a sibling study using tractography-based analysis of the whole brain.

Authors:  Chen-Hao Wu; Tzung-Jeng Hwang; Yu-Jen Chen; Yun-Chin Hsu; Yu-Chun Lo; Chih-Min Liu; Hai-Gwo Hwu; Chen-Chung Liu; Ming H Hsieh; Yi Ling Chien; Chung-Ming Chen; Wen-Yih Isaac Tseng
Journal:  Hum Brain Mapp       Date:  2014-11-04       Impact factor: 5.038

Review 2.  Brain-derived neurotrophic factor and neuropsychiatric disorders.

Authors:  Anita E Autry; Lisa M Monteggia
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

Review 3.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

4.  Expression of the NR2B-NMDA receptor trafficking complex in prefrontal cortex from a group of elderly patients with schizophrenia.

Authors:  L V Kristiansen; B Bakir; V Haroutunian; J H Meador-Woodruff
Journal:  Schizophr Res       Date:  2010-03-29       Impact factor: 4.939

5.  Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.

Authors:  P Malherbe; F Knoflach; M C Hernandez; T Hoffmann; P Schnider; R H Porter; J G Wettstein; T M Ballard; W Spooren; L Steward
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

Review 6.  Hippocampal function, declarative memory, and schizophrenia: anatomic and functional neuroimaging considerations.

Authors:  Alison R Preston; Daphna Shohamy; Carol A Tamminga; Anthony D Wagner
Journal:  Curr Neurol Neurosci Rep       Date:  2005-07       Impact factor: 5.081

Review 7.  Cannabis and psychosis.

Authors:  David M Fergusson; Richie Poulton; Paul F Smith; Joseph M Boden
Journal:  BMJ       Date:  2006-01-21

8.  Evidence for a role of the NOS1AP (CAPON) gene in schizophrenia and its clinical dimensions: an association study in a South American population isolate.

Authors:  Barbara Kremeyer; Jenny García; Hanna Kymäläinen; Naomi Wratten; Gabriel Restrepo; Carlos Palacio; Ana Lucía Miranda; Carlos López; Margarita Restrepo; Gabriel Bedoya; Linda M Brzustowicz; Jorge Ospina-Duque; María Patricia Arbeláez; Andrés Ruiz-Linares
Journal:  Hum Hered       Date:  2008-12-15       Impact factor: 0.444

Review 9.  Epigenetics and psychiatry.

Authors:  Melissa Mahgoub; Lisa M Monteggia
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 10.  The role of phosphodiesterases in schizophrenia : therapeutic implications.

Authors:  Judith A Siuciak
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.